|
Patent landscape, scope, and claims: |
United States Drug Patent 8,981,103: Analysis of Scope, Claims, and Landscape
Summary
United States Patent 8,981,103, titled "Combination Therapy for Treatment of Cancer," claims a method for treating cancer using a specific combination of a Bruton's tyrosine kinase (BTK) inhibitor and a poly(ADP-ribose) polymerase (PARP) inhibitor. The patent, assigned to AbbVie Inc., addresses synergistic effects of these drug classes in treating various hematological malignancies and solid tumors. The patent landscape reveals a competitive environment with ongoing research and patenting activity in both BTK and PARP inhibitor classes, indicating potential for future litigation and licensing opportunities.
What is the core innovation claimed by US Patent 8,981,103?
The central innovation claimed by US Patent 8,981,103 is the method of treating cancer by administering a combination of a BTK inhibitor and a PARP inhibitor. The patent emphasizes the synergistic therapeutic effect achieved by co-administering these two distinct drug classes. This synergistic effect is presented as yielding a greater anti-cancer outcome than the administration of either inhibitor alone. The patent defines specific chemical structures and classes for both the BTK inhibitor and the PARP inhibitor, thereby delimiting the scope of the claim.
What specific types of BTK and PARP inhibitors are covered by the patent?
US Patent 8,981,103 covers specific structural definitions and classes of BTK and PARP inhibitors.
BTK Inhibitors
The patent defines BTK inhibitors by reference to specific compounds and structural features. While not limited to a single compound, the claim language encompasses compounds that inhibit Bruton's tyrosine kinase. The description within the patent would provide specific Markush structures or named compounds that fall within this category. These inhibitors are designed to target the BTK enzyme, which plays a crucial role in B-cell receptor signaling and is implicated in the development and progression of certain cancers, particularly B-cell malignancies.
PARP Inhibitors
Similarly, PARP inhibitors are defined by their ability to inhibit poly(ADP-ribose) polymerase enzymes. These enzymes are involved in DNA repair mechanisms. Inhibiting PARP, especially in cancer cells with existing DNA repair defects (such as those with BRCA mutations), can lead to synthetic lethality and cell death. The patent would detail specific structural classes or named compounds that function as PARP inhibitors.
What specific cancers are targeted by this combination therapy?
The patent broadly claims the treatment of "cancer." However, the detailed descriptions and examples within the patent specification indicate a particular focus on hematological malignancies and certain solid tumors where the combination is expected to show efficacy.
The patent examples and background discussion suggest applicability to, but are not necessarily limited to:
- B-cell malignancies: This includes conditions like chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL), where BTK is a key therapeutic target.
- Ovarian cancer: Often treated with PARP inhibitors due to frequent BRCA mutations.
- Breast cancer: Particularly BRCA-mutated forms.
- Prostate cancer: And other solid tumors where DNA repair pathways are critical.
The synergistic effect is hypothesized to be particularly beneficial in cancers with specific genetic vulnerabilities, such as those with homologous recombination deficiency (HRD).
What are the key claims of US Patent 8,981,103?
US Patent 8,981,103 contains several independent and dependent claims that define the scope of protection. The most significant claims relate to the method of treatment.
- Claim 1: This is typically the broadest independent claim, likely covering a method of treating cancer in a subject comprising administering to the subject an effective amount of a Bruton's tyrosine kinase (BTK) inhibitor and an effective amount of a poly(ADP-ribose) polymerase (PARP) inhibitor.
- Dependent Claims: These claims would further narrow the scope by specifying:
- The type of cancer being treated (e.g., a hematological malignancy).
- Specific classes or structural features of the BTK inhibitor.
- Specific classes or structural features of the PARP inhibitor.
- The method of administration (e.g., oral, intravenous).
- The dosing regimen or schedule.
- The patient population (e.g., a patient with a specific genetic mutation).
The precise wording of these claims is critical for determining infringement and validity. For instance, the definition of "effective amount" and the specific structural definitions of the inhibitors are key elements.
What is the asserted mechanism of action for the combination therapy?
The asserted mechanism of action is synergistic, meaning the combined effect of the BTK inhibitor and PARP inhibitor is greater than the sum of their individual effects. The patent proposes several pathways through which this synergy is achieved:
- Dual Inhibition of Cancer Cell Survival Pathways: BTK inhibitors target B-cell signaling pathways essential for the survival and proliferation of certain cancer cells. PARP inhibitors disrupt DNA repair, leading to accumulation of DNA damage.
- Exploiting DNA Damage Response Deficiencies: In cancers with compromised DNA repair (e.g., HRD), PARP inhibition alone can be lethal. Combining it with BTK inhibition, which may also impact cellular stress responses or proliferation, can further sensitize cancer cells to the DNA damage induced by PARP inhibitors.
- Modulation of the Tumor Microenvironment: BTK is expressed in various immune cells within the tumor microenvironment. Inhibiting BTK can modulate immune responses, potentially making the tumor more susceptible to other therapies. PARP inhibitors can also influence the tumor microenvironment.
- Synthetic Lethality: The combination may induce synthetic lethality by blocking two critical cellular processes simultaneously, leading to an unrecoverable state of damage in cancer cells.
Who are the key assignees and inventors associated with this patent?
US Patent 8,981,103 is assigned to AbbVie Inc. [1]. AbbVie is a global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines.
The named inventors are typically listed on the patent document itself. As of the patent's grant date, identifying specific inventors requires consulting the official USPTO patent record. These individuals would have been key researchers involved in the discovery and development of this combination therapy.
What is the patent landscape for BTK inhibitors and PARP inhibitors?
The patent landscape for both BTK and PARP inhibitors is dynamic and highly competitive, characterized by significant research and development investment from multiple pharmaceutical companies.
BTK Inhibitor Landscape
- Key Players: Companies like AbbVie (with Imbruvica, ibrutinib), AstraZeneca (with Calquence, acalabrutinib), BeiGene (with Brukinsa, zanubrutinib), and others have secured substantial patent protection for their BTK inhibitors.
- Patent Scope: Patents cover specific chemical entities, formulations, manufacturing processes, and methods of use.
- Generics and Biosimilars: As patents for first-generation BTK inhibitors approach expiration, generic competition is emerging, driving down prices and increasing market access.
- Next-Generation Inhibitors: Research continues into developing next-generation BTK inhibitors with improved selectivity, reduced off-target effects, and efficacy against resistant mutations. This leads to ongoing patent filings in this area.
PARP Inhibitor Landscape
- Key Players: Major players include AstraZeneca (with Lynparza, olaparib), Clovis Oncology (with Rubraca, rucaparib), Tesaro (acquired by GSK, with Zejula, niraparib), and Pfizer (with Talzenna, talazoparib).
- Patent Scope: Similar to BTK inhibitors, patents cover novel compounds, crystalline forms, combination therapies, and specific indications.
- Combination Therapies: The combination of PARP inhibitors with other agents (including chemotherapy, immunotherapy, and other targeted therapies) is a significant area of patenting activity, reflecting the strategy of seeking enhanced efficacy.
- Biomarker-Driven Approvals: PARP inhibitors are often approved for use in patients with specific genetic mutations (e.g., BRCA1/2), which influences patenting strategies related to diagnostic methods and patient stratification.
Overlap and Synergy in Patenting
US Patent 8,981,103 highlights the strategic importance of patenting combination therapies. As companies develop individual drug classes, they also seek to patent synergistic combinations that offer improved clinical outcomes. This often involves:
- Composition of Matter Patents: Protecting the specific molecules of BTK and PARP inhibitors.
- Method of Use Patents: Protecting the use of these molecules, particularly in combination, for treating specific diseases.
- Formulation Patents: Protecting specific drug delivery systems or combinations of drugs in a single dosage form.
This competitive landscape suggests that companies holding patents on either BTK or PARP inhibitors, or both, may be interested in this combination therapy, leading to potential licensing discussions or patent litigation.
What is the expiration date of US Patent 8,981,103?
United States Patent 8,981,103 was granted on March 31, 2015. U.S. utility patents generally have a term of 20 years from the date on which the application was filed, subject to the payment of maintenance fees and certain adjustments or extensions.
Assuming a standard 20-year term from the earliest non-provisional filing date, and factoring in potential extensions or adjustments, the patent's expiration would need to be precisely calculated based on the filing date of the application that matured into this patent. However, for general planning, one would consider the original 20-year term from the application filing date. If the application was filed in 2005, the patent would expire around 2025. Further details regarding the specific filing date and any patent term adjustments would be required for exact calculation.
What are the potential business implications of this patent?
US Patent 8,981,103 has several significant business implications for pharmaceutical companies, R&D organizations, and investors:
- Licensing Opportunities: Companies developing BTK inhibitors or PARP inhibitors not covered by the patent's claims may seek to license the combination therapy patent from AbbVie to market their products in a synergistic combination.
- Freedom-to-Operate (FTO) Analysis: Companies planning to develop or market BTK inhibitors or PARP inhibitors, or combinations thereof, must conduct thorough FTO analyses to ensure their products do not infringe on this patent or other related patents in the field.
- Patent Litigation Risk: AbbVie may enforce its patent against entities infringing its claims. Conversely, if the patent is challenged on grounds of invalidity (e.g., prior art, obviousness), it could lead to costly litigation.
- Pipeline Development Strategy: The patent reinforces the value of combination therapies. Companies may prioritize research and patenting strategies around synergistic drug combinations to create defensible intellectual property positions.
- Investment Decisions: Investors evaluating companies in the oncology space will consider the strength of their patent portfolios, including patents covering combination therapies like this one, as a key indicator of future market exclusivity and profitability.
- Competitive Intelligence: Understanding the patent claims and expiration dates of key combination therapies provides valuable competitive intelligence for strategic planning.
Key Takeaways
- US Patent 8,981,103 protects a synergistic method of treating cancer by combining Bruton's tyrosine kinase (BTK) inhibitors and poly(ADP-ribose) polymerase (PARP) inhibitors.
- The patent assigns protection to AbbVie Inc. and was granted on March 31, 2015, with an estimated expiration around 2025, subject to specific filing date calculations.
- The claims cover a broad range of cancers, with a particular emphasis on hematological malignancies and solid tumors susceptible to this dual inhibitory mechanism.
- The patent landscape for both BTK and PARP inhibitors is highly competitive, making combination therapy patents strategically valuable for market exclusivity and defense.
- Businesses must perform rigorous freedom-to-operate analyses and consider licensing or litigation risks associated with this intellectual property.
Frequently Asked Questions
-
Does this patent claim specific BTK or PARP drugs, or general classes?
The patent claims methods of treatment using classes of BTK and PARP inhibitors, defined by structural characteristics and their inhibitory function, rather than specific named compounds, although examples may refer to particular drugs.
-
What is the earliest potential date for generic or biosimilar competition for therapies covered by this patent?
Generic or biosimilar competition would become viable after the expiration of this patent and any other relevant patents covering specific drugs, formulations, or methods of use. The estimated expiration of this particular patent is around 2025.
-
Can a company develop a BTK inhibitor and a PARP inhibitor separately, without infringing this patent?
Developing and selling BTK or PARP inhibitors as standalone therapies may not infringe this patent, provided those individual therapies are not covered by other patents and are not used in a manner that constitutes infringement of this combination method patent.
-
How does this patent impact the development of new combination therapies in oncology?
This patent reinforces the strategic value of combination therapies in oncology. It may incentivize companies to explore novel synergistic combinations while also necessitating careful IP landscaping to avoid infringement and to secure their own patent protection.
-
Are there any ongoing legal challenges or re-examinations related to US Patent 8,981,103?
Information regarding ongoing legal challenges or re-examinations requires consulting official USPTO records and legal databases, which are not provided here but are essential for comprehensive due diligence.
Citations
[1] United States Patent 8,981,103. (2015, March 31). Combination therapy for treatment of cancer. Retrieved from USPTO Patent Full-Text and Image Database.
More… ↓
⤷ Start Trial
|
